论文部分内容阅读
目的:分析单唾液酸四己糖神经节苷酯(GM1)结合康复技术治疗痉挛型脑瘫患儿的临床路径(clinical pathway,CP)效果。方法:将97例脑瘫患儿随机分为常规治疗组(简称对照组)48例和临床路径治疗组(简称CP组)49例,对照组采用常规的治疗模式,CP组采取临床路径模式,对两组患者的住院费用、药费比、院内感染、家长家庭康复知识掌握、家长满意度和粗大运动功能测试量表(GMFM)等方面等进行比较。结果:与对照组比较,治疗组患者的住院费用、药费比和院内感染减少,家长家庭康复知识掌握和家长满意度提高,GMFM有不同程度的改善,均有统计学意义(P<0.05或P<0.01)。结论:临床路径可以降低住院费用、药费比和院内感染,提高患者家长康复知识掌握和满意度,提高临床疗效,创造较好的社会效益,值得临床推广。
OBJECTIVE: To analyze the clinical pathway (CP) effect of monosialotetrahexosyl ganglioside (GM1) combined with rehabilitation on children with spastic cerebral palsy. Methods: A total of 97 children with cerebral palsy were randomly divided into routine treatment group (48 cases) and clinical pathological treatment group (49 cases). The control group received conventional treatment and CP group took clinical path model. Hospitalization costs, drug costs, nosocomial infections, knowledge of parental home rehabilitation, parental satisfaction, and gross motor function test (GMFM) were compared between the two groups. Results: Compared with the control group, hospitalization costs, drug costs and nosocomial infections decreased, parents ’knowledge of family rehabilitation and parents’ satisfaction increased, and GMFM improved to some extent (all P <0.05 or P <0.01). Conclusion: The clinical pathway can reduce the cost of hospitalization, drug costs and nosocomial infections, improve patient mastery and satisfaction of rehabilitation knowledge, improve clinical efficacy and create better social benefits, worthy of clinical promotion.